A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
Latest Information Update: 12 Oct 2021
At a glance
- Drugs SNP-630 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Sinew Pharma
Most Recent Events
- 04 Oct 2021 Status changed from not yet recruiting to completed.
- 24 Mar 2021 New trial record